Pascal Soriot, the CEO of AstraZeneca, talks about how AI is changing drug development, the significance of ‘smart chemo’ and why real innovation requires taking risks.
When Pascal Soriot took the helm at AstraZeneca in 2012, the company was grappling with patent expirations, a lackluster pipeline and poor R&D productivity. Soriot's strategy? Create a culture of risk-taking to spark real innovation.
In the latest episode of Exceptional Leaders / Exceptional Ideas, European Biopharmaceuticals analyst Mark Purcell sits down with Soriot to discuss how “smart chemotherapy” is revolutionizing cancer treatment, why AI is changing every stage of drug development and what he thinks about the future of healthcare.